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AdjuvantsCurrently, there are over 70 licensed vaccines, which prevent the pathogenesis of around 30 viruses and bacteria.
Nevertheless, there are still important challenges in this area, which include the development of more active,
non-invasive, and thermo-resistant vaccines. Important biotechnological advances have led to safer subunit an-
tigens, such as proteins, peptides, and nucleic acids. However, their limited immunogenicity has demanded po-
tent adjuvants that can strengthen the immune response. Particulate nanocarriers hold a high potential as
adjuvants in vaccination. Due to their pathogen-like size and structure, they can enhance immune responses
bymimicking the natural infection process. Additionally, they can be tailored for non-invasivemucosal adminis-
tration (needle-free vaccination), and control the delivery of the associated antigens to a specific location and for
prolonged times, opening room for single-dose vaccination. Moreover, they allow co-association of immuno-
stimulatory molecules to improve the overall adjuvant capacity.
The natural and ubiquitous character of polysaccharides, together with their intrinsic immunomodulating prop-
erties, their biocompatibility, and biodegradability, justify their interest in the engineering of nanovaccines. In
this review,we aim to provide a state-of-the-art overview regarding the application of nanotechnology in vaccine
delivery, with a focus on the most recent advances in the development and application of polysaccharide-based
antigen nanocarriers.
© 2015 Elsevier Inc. All rights reserved.Contents1. Challenges and advances in vaccine development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1280
1.1. Biotechnology and antigen development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1281
1.1.1. Recombinant proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1281
1.1.2. Peptides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1281
1.1.3. Genetic vaccination . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1281
1.2. Vaccine adjuvants and antigen nanoengineering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1281
1.2.1. Molecular adjuvants . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1281
1.2.2. Nanoengineering of antigens: antigen delivery systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1282
2. The potential of nanotechnology for vaccine delivery . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1282
3. Nanoengineering of vaccines using polysaccharides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1283
3.1. Chitosan as a biomaterial for antigen nanoengineering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1284
3.1.1. Protein nanovaccines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1284
3.1.2. Nucleic acid-based nanovaccines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1286
3.2. Dextran as a biomaterial for nanoengineering antigens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1287
3.2.1. Protein nanovaccines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1287
3.2.2. Nucleic acid-based nanovaccines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1288
3.3. Mannans as biomaterials for nanoengineering antigens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1288
3.3.1. Protein nanovaccines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1288
3.3.2. Nucleic acid-based nanovaccines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1288. de la Fuente).
1280 A.S. Cordeiro et al. / Biotechnology Advances 33 (2015) 1279–12933.4. Beta glucans as biomaterials for nanoengineering antigens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1289
3.4.1. Protein nanovaccines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1290
3.4.2. Nucleic acid-based nanovaccines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1290
4. Concluding remarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1290
5. Future perspectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1290
Acknowledgments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1290
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12901. Challenges and advances in vaccine development
Throughout the last decades, vaccination has played a fundamental
role in the prevention of severe infectious diseases, and even in the
eradication of some of them. Despite the advances achieved to date,
significant challenges still need to be faced in order to gradually increase
vaccine coverage. These include not only the development of new
vaccines against certain pathogens such as human immunodef-
iciency virus (HIV), malaria and tuberculosis, among others, but alsoFig. 1. Advances in biological andmicrobiological technologies have increased the knowledge o
these antigens are less effective in inducing protective immune responses and therefore requi
particulate delivery systems. Among these, polysaccharide-based nanosystems have demonstrthe development of single-dose andneedle-free vaccines intended to im-
prove patient compliance and reduce associated costs. Lastly, the produc-
tion of formulations that can avoid the cold chain of transport represents
a keystone to improve vaccination worldwide. Progress in both antigen
and adjuvant development has led to the recognition of the value of
nanotechnology to deal with the above indicated challenges. For the
preparation of nanovaccines, different immunomodulating biomaterials
have been proposed, including polysaccharides. This innovative ap-
proach is the main focus of this review and is summarized in Fig. 1.f pathogens and led to the development of newer and safer subunit antigens. Nevertheless,
re a parallel development of potent adjuvants such as immunomodulating molecules and
ated potential to be successfully used in vaccine formulations.
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The first commercialised vaccines against rabies, poliomyelitis, teta-
nus and childhood tuberculosis, among others, were based on the atten-
uation of pathogens and toxins. However, the potential toxicity and the
difficulty in carrying out this process with complex pathogens, such as
HIV and hepatitis C virus (HCV), has led to the search for optimised an-
tigens (Delany et al., 2014). Advances in biotechnology and an increased
knowledge of the pathogen characteristics have led to the development
of newer and safer subunit antigens, in particular proteins, peptides and
nucleic acids (Nabel, 2013).
1.1.1. Recombinant proteins
Recombinant DNA technology has allowed the production of several
proteins with antigenic activity, using expression vectors such as bacte-
ria or yeast. A well-known example of this application is the production
of the hepatitis B surface antigen (rHBsAg) in Escherichia coli, which has
led to the first recombinant protein-based vaccines reaching themarket
using alum as adjuvant (Engerix-B® from GlaxoSmithKline Biologicals
and Recombivax HB® from Merck & Co., Inc.). Similarly, antigens of
the human papillomavirus (HPV), expressed in Saccharomyces cerevisae
and Trichoplusia ni, are commercialised as Gardasil® (Merck & Co., Inc.)
and Cervarix® (GlaxoSmithKline Biologicals), with alum and AS04®
(a combination of alum and monophosphoryl lipid A (MPLA)) as adju-
vants, respectively. Other pathogens for which recombinant protein
antigens have been identified and studied include hepatitis C and E
and rotavirus (Ohtake and Arakawa, 2013).
The concept of “reverse vaccinology”, focussed on the scan of the
whole genome of the pathogen for identification of antigenic protein
candidates, represented an important advance towards the develop-
ment of new vaccines. This strategy has led to the development, for ex-
ample, of a new meningococcal vaccine, commercialised in Europe
under the brand name of Bexsero® (by Novartis Vaccines). Vaccines
against pathogens such as Streptococcus pneumoniae and Leishmania
infantum, among others, have also been investigated using this ap-
proach (Donati and Rappuoli, 2013).
1.1.2. Peptides
The above indicated antigenic proteins still have important limita-
tions such as complex production processes, difficult purification
steps, and instability in a liquid form. More importantly, protein-based
vaccines may induce autoimmunity and allergic reactions, as reported,
for example, in the development of a vaccine against groupA Streptococ-
cus (GAS) (Batzloff et al., 2004; Skwarczynski and Toth, 2011). For
these reasons, efforts are currently focussed on the production of
small peptides as antigens. These antigenic peptides can be identified
through the analysis of specific antibody-inducing regions within larger
proteins (epitopes), and are generally obtained through simple synthe-
sis with high purity, in large scale, and at a lower cost (Gori et al., 2013;
Purcell et al., 2007; Rosendahl Huber et al., 2014; Skwarczynski and
Toth, 2011). Several peptide-based vaccine formulations have already
reached the clinical development phase, as it is the case for some pre-
ventive HIV vaccines (Girard et al., 2006) as well as some therapeutic
anticancer vaccines (Mohit et al., 2014; Ott et al., 2014).
Overall, it can be stated that proteins and peptides have improved
the vaccine safety profile in comparisonwith live attenuated pathogens,
however, their poor immunogenicity is definitely hindering their
development and success (Gori et al., 2013; Purcell et al., 2007). For
this reason, it is essential to advance in the design of novel adjuvants
that may help providing these vaccines with a robust immune response
(Fox et al., 2013).
1.1.3. Genetic vaccination
In the last decades, nucleic acid-based vaccines have gained increas-
ing attention (Deering et al., 2014; Xiang et al., 2010). Essentially,
nucleic acids such as plasmid DNA (pDNA) and messenger RNA(mRNA) allow in situ production of the antigen by the cellular machin-
ery of the host. This strategy mimics the natural infection by intracellu-
lar pathogens as it leads to the local formation of the antigenicmolecule.
Moreover, nucleic acids can be tailored to express antigens that are
chemically or structurally different from their native form, with the in-
tention of improving their immunogenicity (Alpar et al., 2005; Deering
et al., 2014; Kramps and Probst, 2013). The main limitation of this ap-
proach is the low level of gene expression achieved upon administra-
tion, a limitation that can be overcome by designing effective viral and
non-viral transfection vectors (Alpar et al., 2005; Mazid et al., 2013).
Plasmid DNA vaccination, based on the administration of selected
antigen-encoding DNA through a plasmid vector, has been applied to
prevent diseases such as malaria and HIV and also as a therapeutic ap-
proach in cancer immunotherapy. Some of these formulations have al-
ready reached the clinical development phase, as recently reviewed by
Mazid et al. (Liu, 2003; Mazid et al., 2013). Nevertheless, the risk of ge-
nome integration and long-term effects of these vaccines are yet to be
clarified (Schalk et al., 2006). As an alternative, messenger RNA has
raised particular attention, with preclinical proofs-of-concept described
for prophylactic influenza vaccination and some formulations in clinical
development for anticancer immunotherapy (Deering et al., 2014;
Kramps and Probst, 2013).
1.2. Vaccine adjuvants and antigen nanoengineering
Alum has been the traditional adjuvant of choice for vaccines,
though its mechanism of action is not yet completely understood. It
also has specific limitations such as the necessity to be stored at
low temperature, a limited efficacy for peptide antigens, and inability
to generate Th1 (cellular) immune responses (Azmi et al., 2014;
Bomford, 1989; Lindblad, 2004). The need to overcome these limita-
tions has stimulated the search for new adjuvants. As a consequence,
there is currently a large variety of adjuvants, which for the purpose of
this review we have classified in two groups, molecular adjuvants or
immunostimulatory molecules and antigen delivery systems produced
by the nanoengineering of antigens.
1.2.1. Molecular adjuvants
Small molecules, targeted at specific receptors present on immune
cells (pattern recognition receptors (PRRs)), such as Toll-like receptors
(TLRs), have the ability to trigger stronger immune responses
(Demento et al., 2011). The most studied molecules are agonists for
TLRs, as for example CpG oligonucleotides (TLR 9), poly(I:C) (TLR
3) or imiquimod (TLR 7/8), which have already been evaluated for
their adjuvant properties in vaccines against malaria, hepatitis B, influ-
enza, aswell as in different therapeutic anticancer vaccines (Steinhagen
et al., 2011).
Other molecules such as bacterial toxins (cholera toxin, E. coli heat-
labile toxin and others), saponins (Quil-A or QS-21) and cytokines,
are also used as immunostimulants in vaccine formulations. In particu-
lar bacterial toxins are known to enhance the immune response by
targeting the antigen to the M cells in the intestinal tract, thereby
boosting a strong humoral response at a mucosal level. An example of
these toxins is cholera toxin (recombinant B subunit), which is used
as an adjuvant for a commercialized oral cholera vaccine (Hill et al.,
2006). Another example refers to a transdermal patch containing
heat-labile E. coli enterotoxin for the enhancement of the immune re-
sponse against pathogens such as E. coli and influenza (Behrens et al.,
2014; Frech et al., 2008; Glenn et al., 2009). Nevertheless, a major limi-
tation of these toxins is related to the immune response that can be
generated against themselves rather than against the associated antigen
(Mallapragada andNarasimhan, 2008; Reed et al., 2009;Wilson-Welder
et al., 2009).
In the case of saponins, which are plant-derived triterpene glyco-
sides, a detoxified derivative (QS-21) of Quil-A (fromQuillaja saponaria)
has been successfully included in particulate formulations such as
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AS02™ (squalene oil-in-water emulsion also containing MPLA), cur-
rently under clinical development for malaria vaccines (Kester et al.,
2014; The RTS.S Clinical Trials Partnership, 2014). Also, the inclusion
of saponins in immunostimulating complexes (ISCOMs) has been eval-
uated in vaccination against influenza, toxoplasmosis or Epstein–Barr
virus-induced tumours, among others, achieving protective immunity
in clinical studies (Barr et al., 1998; Sun et al., 2009).
With respect to cytokines, IL-2, IL-12 and IFN-γ are some of the
molecules that have been studied for immune response modulation,
both at preclinical and clinical levels, though some toxic effects have
been observed with high doses in human studies (Hedlund et al.,
2002; Hughes, 1998; Lynch et al., 2003).
1.2.2. Nanoengineering of antigens: antigen delivery systems
Macromolecules such as polymers, among them polysaccharides
(as reviewed in Section 3), lipids such as MPLA and squalene, as well
as several phospholipids, have also been used in some cases for the
nanoengineering of antigens, leading to the formation of nanocarriers
or antigen delivery systems (Fox, 2009; Perrin-Cocon et al., 2006).
Specific moieties, such as pathogen-associated molecular patterns
(PAMPs) that can be recognized by PRRs, are in some occasions natural-
ly present in these macromolecules, or can be synthetically included in
their structures to potentiate their function (Demento et al., 2011;
Mora-Solano and Collier, 2014). In the case of MPLA and squalene,
their recognized immunomodulation features have led to their inclu-
sion in marketed vaccines, or as components of approved adjuvants
such as MF59, AS03™ (in the case of squalene) and AS04™ (in the
case of MPLA), as well as in other formulations still in preclinical and
clinical development (Rappuoli et al., 2011).
Nanoengineering approaches can be used to associate antigens to
delivery carriers made of specific biomaterials, normally recognized
for their adjuvant properties. These delivery carriers are able to trans-
port and control the release of antigens to the cells where they should
exert a biological activity. Polymeric nanoparticles, ISCOMs, liposomes
and lipid nanoparticles, among others, are included in this category
(Azmi et al., 2014; Correia-Pinto et al., 2013; González-Aramundiz
et al., 2012; Sahdev et al., 2014).
In general, it is recognized that the depot effect generated by thema-
jority of antigen delivery systems after subcutaneous injection, allowing
their uptake by the antigen presenting cells, is an attractive feature of
this type of adjuvants (Aguilar and Rodríguez, 2007; Bachmann and
Jennings, 2010).Moreover, they are able tomimic the particulate nature
of pathogens, therefore increasing the possibilities of an effective im-
mune response (De Temmerman et al., 2011). In this context, nanotech-
nology is expected to have a significant impact, as will be discussed in
the following section.
2. The potential of nanotechnology for vaccine delivery
The use of technologies and biomaterials at nanometric scale in
therapeutics and diagnostics is a growing researchfield since the second
half of the 20th century (Duncan and Gaspar, 2011). A large variety of
nanoparticulate systems has been developed throughout the past
decades to improve the delivery, targeting and efficacy of drugs, biomol-
ecules, nucleic acids and antigens (Etheridge et al., 2013). Depending on
the components and methodology chosen, it is possible to develop a
wide range of nanostructures, as for example (i) polymeric nanoparti-
cles, based on a matrix-type entanglement of selected polymers,
(ii) oil-in-water (O/W) nanoemulsions, consisting in oil nanodrops
stabilized by adequate surfactants, (iii) nanocapsules, which are
polymer-coated nanoemulsions, forming a core–shell nanostructure,
and (iv) lipid-based nanosystems, such as liposomes and solid lipid
nanoparticles, among others.
In the area of vaccination, nanotechnology has led to the devel-
opment of nanostructures holding specific advantages for antigendelivery. First of all, as mentioned before, due to their particulate
structure and nanometric size, similar to the ones of virus and bacteria,
nanoparticles can mimic the natural infection process and be taken-up
by the antigen presenting cells (APCs), thereby leading to enhanced im-
mune responses (Bachmann and Jennings, 2010; Reddy et al., 2006b;
Storni et al., 2005; Zolnik et al., 2010). A number of authors have report-
ed that particles in the nanometric range are particularly suitable
for their interaction with the immune system (Fifis et al., 2004; Joshi
et al., 2013; Reddy et al., 2007). In addition, in our lab, working with
PLA–PEG micro and nanoparticles, we have also observed that
200 nm-nanoparticles can enhance the transport of the antigen through
the nasal mucosa more efficiently than microparticles, (either 1 or
5 μM) after intranasal administration (Vila et al., 2005). However,
there is still some controversy regarding this issue, with other works
supporting the idea that microparticles can elicit stronger immune
responses (Gutierro et al., 2002; Kanchan and Panda, 2007). This dis-
agreement may come from the difficulty to compare different studies,
as many variables account for the total outcome of the immune re-
sponse, such as the constituting biomaterials, the nature and doses of
antigen, and the route of administration (Oyewumi et al., 2010). It has
also been hypothesized that using nanoparticlesmay favour cellular im-
mune responses through optimal interactions with CD8+ dendritic cell
(DC) subsets (Bachmannand Jennings, 2010). For example, usingmodel
carboxilated polystyrenemicro (2 μm)and nanoparticles (40 nm), load-
edwith ovalbumin (OVA) (Fifis et al., 2004), it was shown that nanopar-
ticles were able to elicit significantly higher IgG and T-cell responses.
Finally, it has been reported that a size below 100 nm is desirable if
the purpose is to facilitate the transport of nanoparticles from the sub-
cutaneous tissue up to the lymph nodes,where the antigenswill be pre-
sented to mature immune cells for an adaptive immune response
(Reddy et al., 2006a, 2007).
Nanostructures have also shown an interestingpotential formucosal
antigen delivery, due to their ability to interact and get across mucosal
barriers (Csaba et al., 2009; des Rieux et al., 2006). This property is
mainly related to the particle size (Desai et al., 1996; Jani et al., 1990),
and also to the composition, being favoured when the systems include
mucoadhesive materials such as chitosan (Grabovac et al., 2005). More-
over, our group was pioneer in demonstrating that the modification of
nanocarriers with polyethylene glycol (PEG) units, in different degrees,
was also responsible for improved transport of those systems across the
nasal mucosa (Tobío et al., 1998). Overall, the increased interaction of
these systems with the mucosae boosts the antigen presentation in
those areas, where the natural entrance of several pathogens usually
happens, therefore mimicking the natural infection process. Mucosal
antigen delivery, or needle-free vaccination, allows overcoming impor-
tant limitations associated to parenteral immunization such as the high
cost of preparation, the need for specific administration materials
(needles and syringes) and specialized technical staff, and is also more
likely to be well accepted by patients, altogether resulting in an im-
proved vaccine coverage (Chadwick et al., 2010; Giudice and Campbell,
2006).
Finally, another important advantage of nanosystems in vaccine de-
livery is the possibility to co-encapsulate additional immunostimu-
latory molecules, such as the ones described in Section 1.2.1, with the
purpose of increasing the overall adjuvant capacity. As an example,
TLR agonists such as CpG, poly(I:C) (Peine et al., 2013) or imiquimod
(Vicente et al., 2013b), have been associated to dextran nanoparticles
and chitosan nanocapsules, respectively. Thesemolecules promote spe-
cific receptor-based recognition of the nanovaccines and the conse-
quent cell activation, strengthening the elicited immune response.
To highlight the potential of nanoparticles in vaccination, it is worth
mentioning the formulations that have already reached themarket and
others in advanced clinical stages of development. Nanoemulsions, such
as AS03™ (an oil-in-water nanoemulsion containing squalene, DL-α-
tocopherol and Tween® 80) (Roman et al., 2010) orMF59™ (also squa-
lene oil-in-water nanoemulsion stabilized with Tween® 80 and Span®
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namely Pandemrix™ (from GlaxoSmithKline Biologicals), and Fluad™
and Focetria™ (from Novartis), respectively. Virosomes, composed
of a phospholipid membrane incorporating viral glycoproteins, are
present in commercialized Hepatitis A and influenza vaccines, Epaxal™
and Inflexal™ (both from Crucell), respectively (Usonis et al., 2003).
Other nanometric formulations such as AS01™ (liposomes based on
MPLA) (Leroux-Roels et al., 2010), AS02™ (squalene oil-in-water emul-
sion also containingMPLA) (Aide et al., 2011), and onepolymeric carrier
based on PLGA, among others, are currently under clinical development
for different vaccines, as described in Table 1. Considering this, it is clear
that nanometric delivery systems are in the spotlight for their potential
in vaccination.
3. Nanoengineering of vaccines using polysaccharides
In the late 70s, the work of Kreuter and Speiser opened the way for
the specific use of polymers, such as polymethylmethacrylate, as mate-
rials for the engineering of antigen nanocarriers (Kreuter and Speiser,
1976). Since then, a significant number of studies have put in evidence
the potential of nanoparticles to enhance the immune response against
different antigens in a sustained and prolonged way (Correia-Pinto
et al., 2013; González-Aramundiz et al., 2012; Reddy et al., 2006b;
Rice-Ficht et al., 2010; Vicente et al., 2010). Our group, being particularly
active in the field, pioneered the encapsulation of model proteins and
antigens within poly(lactic-co-glycolic acid) (PLGA) (Blanco and
Alonso, 1997) and polylactic acid–polyethylene glycol (PLA–PEG) nano-
particles (Tobío et al., 1998). Interestingly, this work was followed by
a great number of authors (Danhier et al., 2012), whose contribu-
tions have led to the clinical development of PLGA-based nanovac-
cines (www.clinicaltrials.gov). All along this engineering trajectory, it
became clear that a major inconvenience of this biomaterial was the
degradation of the antigen encapsulated in the course of the polymer
degradation (Alonso et al., 1994; Tobío and Alonso, 1998). Although
specific formulation strategies were found to significantly reduce
this effect over the encapsulated antigens (Sánchez et al., 1999;
Schwendeman et al., 1996), overall the results achieved using PLGA-Table 1
Nanoengineered antigen formulations in clinical development.
Delivery System Antigen
MF59 Influenza (H5N1 inactivated virus)
Influenza (H7N9 inactivated virus)
Influenza (killed virus, trivalent subunit vaccine)
RSV (RSV F protein)
CMV (gp B)
MF59 & AS03 Influenza (H7N9 inactivated virus)
AS03 Influenza (H5N1 inactivated virus)
AS03 & AS01 Dengue (inactivated virus)
AS01 Malaria (FMP012; FMP2.1; RTS,S proteins)
AS02 Malaria (FMP1; RTS,S proteins)
ISCOM HSV (GEN-003 protein)
Malaria (viral vector with ME-TRAP protein)
Influenza (H7N9 VLP)
Iscomatrix Cancer (tumour cell lysates)
Hydrogel Influenza (Act-HIB® vaccine)
Virosomes Hepatitis A (inactivated virus)
Candidiasis (n.d.)
PLGA microspheres Cancer (HER-2/Neu peptide)
Abbreviations: RSV, respiratory syncytial virus; CMV, cytomegalovirus; gp B, glycoprotein B; Hbased nanoengineering persuaded us and others to search for new bio-
materials which might have a mild interaction with antigens.
Naturally occurring polymers, in particular polysaccharides
attracted our attention in the mid 90s as biomaterials for antigen
nanoengineering. With this goal in mind, we reported for the first
time the production of nanoparticles consisting of assemblies of pro-
teins and chitosan (Calvo et al., 1997a), as described in the following
section. Following this, other authors have proposed the use of polysac-
charides, i.e. dextran,mannan and beta glucans for the nanoengineering
of vaccines (Petrovsky and Cooper, 2011). These latter biomaterials are
found in the cell walls of several pathogens such as bacteria or yeast, a
characteristic that provides them with intrinsic targeting abilities to
APCs (acting as PAMPs on the PRRs present in these cells) and, conse-
quently, a natural capacity to enhance the immune response against
the associated antigens (Demento et al., 2011; Dykstra et al., 2011;
Mora-Solano and Collier, 2014; Petrovsky and Cooper, 2011). Other im-
portant features such as high biocompatibility and low toxicity make
polysaccharides particularly interesting for pharmaceutical develop-
ment purposes.
Another specific advantage associated to the use of polysaccharide-
based antigen nanocarriers is related to the technologies used to pro-
duce them. These technologies rely on physicochemical processes
such as ionic gelation (Calvo et al., 1997c), complexation (Kean et al.,
2005) and solvent displacement (Calvo et al., 1997b), among others.
These are generally simple and mild techniques, which minimize the
use of solvents and high-energy sources, easy to scale-up, and impor-
tantly, suitable for the association of labile biomolecules (Vauthier and
Bouchemal, 2011). Apart from selecting an appropriate technology,
other relevant technical aspects for the development of nanovaccines,
i.e. the stability of the antigen, in terms of biological activity, and the sta-
bility of the formulation during storage, are to be considered at early
stages of development (Amorij et al., 2012; Chen and Zehrung, 2013).
Selection of rawmaterialswith pharmaceutical quality, i.e. produced ac-
cording to specific criteria that assure their high purity and adequate
characteristics for use in humans and with good inter-batch reproduc-
ibility, are also important topics to take into consideration in the process
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deserves a deeper analysis of the published material concerning
polysaccharide-based nanosystems in vaccination. For this reason, the
characteristics of the main polysaccharides with described adjuvant
properties, as well as their application in the development of nano-
vaccines, are detailed as following.
3.1. Chitosan as a biomaterial for antigen nanoengineering
Chitosan (CS) is a naturally occurring polymer composed of a linear
backbone of D-glucosamine and N-acetyl-D-glucosamine monomers
connected through β-(1,4) bonds. This polysaccharide is mainly obtain-
ed from the deacetylation of chitin, present in the exoskeleton of crusta-
ceans and squids, though other sources such as fungi have also been
reported (García-Fuentes and Alonso, 2012; Gomes et al., 2014). One
of the most relevant characteristics of chitosan is the possibility to
modulate its degree of acetylation and therefore the number of amino
groups (Gomes et al., 2014). Its cationic character allows electrostatic
interactions with antigens that are negatively charged in physiological
conditions, and is also responsible for its ability to interactwithmucosal
surfaces (Islam et al., 2012; Sogias et al., 2008).
Some authors have indicated potential chitosan immunomodulatory
properties based on some in vitro and in vivo studies performed using
chitosan in solution. More precisely, Peluso et al. found that chitosan
solutions can activate peritoneal ratmacrophages through the enhance-
ment of nitric oxide secretion in vitro (Peluso et al., 1994). On the other
hand, Porporatto et al. have reported the ability of chitosan to trigger
local and systemic immune responses, evidenced by the enhancement
of cytokine production upon oral administration of a single 3 mg dose
of the polysaccharide in solution to rats (Porporatto et al., 2005). Finally,
Zaharoff et al. evaluated the adjuvant potential of a chitosan solution
(1mg dose), given subcutaneously, in comparisonwith phosphate buff-
ered saline solution (PBS) and with common adjuvants such as alum
and Incomplete Freund's Adjuvant (IFA), using amodel protein antigen,
β-galactosidase (Zaharoff et al., 2007). Results have shown the ability of
chitosan to induce humoral and cellular responses,whichwere superior
to the non-adjuvanted formulation and the alum-adjuvanted one and
equivalent to the ones achieved using IFA. Nevertheless, these immuno-
modulatory properties are still under question and could be related to
the uncontrolled precipitation of chitosan at physiological pH, and also
to the source and quality of chitosan used (García-Fuentes and Alonso,
2012).
With respect to the biocompatibility and biodegradability of chito-
san, it is worth mentioning that chitosan has a “generally recognized
as safe” (GRAS) status granted by the United States Food and Drug
Administration (FDA). Chitosan has been used for a long time as a die-
tary supplement for the prevention of fat absorption, and as a compo-
nent of wound dressings (Boateng et al., 2008). On the other hand,
chitosan is present in newnasal vaccine formulations againstmeningitis
and Norovirus, which are under clinical development (Atmar et al.,
2011; Huo et al., 2005). In addition, it is present in a vaccine hydrogel
formulation against influenza, for intramuscular injection (Neimert-
Andersson et al., 2014). Overall, chitosan is therefore considered as
one of the most advanced polymers in the regulatory path for the indi-
cation of vaccination. Taking this into account, and also preclinical evi-
dence of the potential of chitosan-based nanocarriers as adjuvants for
mucosal and parenteral immunization (Table 2), it could be expected
that chitosan nanoformulations could enter clinical trials in the oncom-
ing years.
3.1.1. Protein nanovaccines
3.1.1.1. Parenteral vaccination with chitosan-based nanovaccines. As
indicated, chitosan nanoparticles, developed for the first time in
the 90s (Calvo et al., 1997c), have been widely studied for the delivery
of proteins and antigens (Arca et al., 2009; García-Fuentes andAlonso, 2012). For example, chitosan nanoparticles associating rHBsAg
exhibited an adjuvant effect that was higher than that of alum,
after intramuscular administration to mice (Prego et al., 2010). Other
studies have been addressed to co-associate immunostimulant mole-
cules, i.e. CpG, and rHBsAg in chitosan nanoparticles. This vaccine
formulation increased the IgG titres in comparison with the antigen in
solution, upon subcutaneous administration to mice (Borges et al.,
2008). Chitosan nanoparticles have been additionally reported for
their potential in a single-dose vaccination strategy for rHBsAg
(Lugade et al., 2013). The results of this study indicated that after a
single intraperitoneal, intramuscular or subcutaneous injection of the
nanoparticles, the response achieved was stronger and lasted longer
than the one elicited by a single dose of RecombivaxHB® (alum-associ-
ated rHBsAg), given intraperitoneally.
A different type of chitosan-based nanocarrier, i.e. chitosan
nanocapsules, originally disclosed by our group (Prego et al., 2006)
was similarly proposed for a single-dose immunization schedule with
rHBsAg (Vicente et al., 2013a). Additionally, we developed a freeze-
dried formulation in order to improve the preservation of the vaccine.
The results observed upon a single intramuscular administration to
mice indicate that the IgG levels were comparable to those obtained
after vaccination with the alum-adsorbed antigen in a prime-boost
scheme (weeks 0 and 4). We could also prove that these nanocap-
sules were adequate for the co-encapsulation of the TLR 7/8-agonist
imiquimod (Vicente et al., 2013b), a formulation approach for nasal
immunization, further discussed in the next section. More recently,
we conducted experiments to assess the biodistribution of these
nanocapsules after subcutaneous injection (Vicente et al., 2014). The re-
sults evidenced the formation of a depot, followed by a slow drainage of
the nanocapsules towards the lymph nodes, where they accumulate
(for illustration see Fig. 2). These results allowed us to conclude that
this biodistribution profilewas responsible for the long-lasting adjuvant
effect observed for chitosan nanocapsules.
3.1.1.2. Mucosal vaccination with chitosan-based nanovaccines. Apart
from the promising results obtained with parenteral immunization
using chitosan nanovaccines, a great deal of effort has been addressed
to the development of chitosan-based nanovaccines intended formuco-
sal vaccination. Our group pioneered the development of the first
chitosan-based nanovaccine as a needle-free vaccination strategy (Vila
et al., 2004). Our results showed that after intranasal administration to
mice, chitosan-based tetanus toxoid (TT) nanovaccine led to high and
long-lasting IgG levels, which were comparable to those elicited by
the alum-adsorbed vaccine administered intramuscularly (Vila et al.,
2004). More recently, chitosan nanoparticles were studied for the asso-
ciation of the hemagglutinin protein of H1N1 influenza virus. After
intranasal administration of hemagglutinin-loaded chitosan nano-
particles to mice, both the systemic and mucosal antibody levels (IgG
and IgA) were significantly enhancedwith respect to the controls (anti-
gen in solution), and a T cell response was also reported. Importantly,
after being challenged through the same route with the virus, the
animals receiving the nanovaccine presented higher survival rates
(Sawaengsak et al., 2014). In another study, chitosan nanoparticles
were loadedwith Streptococcus equibacterial proteins and administered
intranasally to mice. The results showed enhanced IgG and IgA re-
sponses as compared to those elicited by the antigen-loaded liposomes
and the corresponding empty nanoparticles and liposomes (Figueiredo
et al., 2012).
Our group has also explored the potential of co-encapsulation of
rHBsAg and the immunostimulant imiquimod into chitosan nano-
capsules, for enhancing the immune response following intranasal vac-
cination (Vicente et al., 2013b). The results obtained in mice evidenced
an enhanced, specific and Th1/Th2 balanced immune response, which
was significantly higher than the one observed for rHBsAg-loaded chito-
san nanocapsules (without imiquimod) and the control rHBsAg-loaded
nanoemulsion (Fig. 3). These results highlight the positive effect of co-
Table 2
In vivo evaluation of chitosan-based nanovaccines.
Nanosystem Antigen Administration
route
In vivo efficacy results Reference
Nanoparticles OVA IM, IN After IM immunization (single dose), OVA-loaded TMC nanoparticles and TMC–OVA
nanoconjugates provided higher IgG titres than the controls, and increased DC uptake
and activation. IN immunization (2 doses) elicited strong and balanced IgG and IgA levels.
Slütter et al. (2010b,c)
Higher IgG levels were achieved with TMC nanoparticles in comparison with PLGA
nanoparticles (coated or not with TMC), irrespective of the administration route (3 doses).
Slütter et al. (2010a)
Intraduodenal TMC or chitosan nanoparticles (2 doses), increased the IgG levels and induced DC
maturation in comparison with OVA in solution.
Slütter et al. (2009)
IN, ID TMC nanoparticles co-encapsulating additional adjuvant molecules (2 doses) were
compared. In terms of IgG and IgA levels, LPS was best in both routes, followed by MDP
for IN route and CpG for ID route.
Bal et al. (2012)
IN, TD Covalently-linked TMC:HA nanoparticles elicited higher IgG levels than free OVA and
conventional TMC:HA nanoparticles based on electrostatic interactions (2 doses).
Verheul et al. (2011)
rHBsAg IM Significantly higher IgG levels in comparison with alum-adsorbed antigen (2 doses). Prego et al. (2010)
IP Stronger and longer-lasting IgG levels elicited in a single-dose schedule in comparison
with commercial vaccine. Results with the nanovaccine were comparable irrespective
of IP, IM or SC administration route.
Lugade et al. (2013)
SC Significantly higher IgG levels co-encapsulating CpG (2 doses) than with the antigen in
solution. Coating the antigen-loaded nanoparticles with alginate and co-administering
a CpG solution shifted the response towards Th1/Th2 balance and increased IFN-γ levels
(cellular response).
Borges et al. (2008)
pRc/CMV-HBs
(plasmid)
IN Protective and Th1-biased IgG levels, as well as high IgA levels in nasal, salivary and
vaginal secretions, elicited after 2 immunizations.
Khatri et al. (2008b)
TT IgG levels upon 3 doses were higher than those reported with the antigen in solution,
and comparable to IM alum-adsorbed vaccine.
Vila et al. (2004)
Nanoparticles TT IN TMC nanoparticles (2 doses) elicited similar response than chitosan nanoparticles,
which were significantly higher than the antigen in solution.
Sayın et al. (2008)
Hemagglutinin Two doses of the nanovaccine elicited high IgG and IgA levels, induction of IFN-γ
production by spleen cells (cellular response) and an increased survival of challenged
animals up to 100%.
Sawaengsak et al. (2014)
Streptococcus equi Higher IgA levels, increased mucosal uptake and Th1/Th2 balanced responses in
comparison with cationic liposomes (2 doses).
Figueiredo et al. (2012)
Antigen-encoding
plasmids
IM Plasmid encoding Chlamydia trachomatis proteins. High local (mice thigh muscles) and
systemic (mice spleens) protein expression levels after a single-dose administration.
Cambridge et al. (2013)
Plasmid encoding 3 T-cell epitopes of Esat-6 (Mycobacterium tuberculosis antigen). Strong
Th1 and CTL responses as well as protection against challenge upon 3 immunizations.
Feng et al. (2013)
SC/IN Plasmid encoding antigen 85B (M. tuberculosis). Co-encapsulation of another plasmid
encoding an autophagy-inducing factor (myc-mTOR). Strong IgG and cytokine
(IL-4 and IFN-γ) levels after SC prime and two IN boosts.
Meerak et al. (2013)
IN Plasmid encoding pHSP65pep (M. tuberculosis). Strong antibody and T-cell responses and
increased protection against challenge after 4 immunizations.
Ai et al. (2013)
Plasmid encoding the SARS-CoV nucleocapsid protein. Particles functionalized with a
protein vector for DC targeting (bfFP) and a DC maturation stimulus (aCD40) (2 doses)
showed better targeting to DCs and increased mucosal response.
Raghuwanshi et al.
(2012)
Oral Plasmid encoding Der p 2 (house dust mites allergen). Antibody (IgG2 and IgE) and cytokine
(IFN-γ and IL-4) levels correlated with the minimization of the allergic process (2 doses).
Li et al. (2009)
Plasmid encoding Rho1-GTPase (Schistosoma mansoni antigen). Significantly reduced liver
granulomatosis and worm burden (after challenge) in comparison with controls (3 doses).
Oliveira et al. (2012)
Nanocapsules rHBsAg IM, IN A single IM dose of the vaccine prototype elicited similar IgG levels as two IM doses of
alum-adsorbed antigen. Including imiquimod (TLR-7/8 agonist) enhanced a specific
Th1-biased immune response through IN route.
Vicente et al. (2013a,b)
Liposomes Antigen-encoding
plasmids
IN Plasmid encoding HBsAg. Glycol chitosan-coated liposomes (2 doses) elicited seroprotection
and increased IgA levels in nasal, vaginal and salivary secretions in comparison with controls.
Khatri et al. (2008a)
Plasmid encoding Streptoccocus mutans surface antigen. Chitosan-coated liposomes (2 doses)
selectively released DNA at pH 7.4 (cellular cytoplasm), increased nasal residence time and
enhanced IgA levels, in comparison with DNA-loaded chitosan nanoparticles.
Chen et al. (2013)
Abbreviations: rHBsAg, recombinant hepatitis B surface antigen; OVA, ovalbumin; TT, tetanus toxoid; IM, intramuscular; IP, intraperitoneal; SC, subcutaneous; IN, intranasal; ID, intrader-
mal; TD, transdermal; IgG, immunoglobulin G; IFN-γ, interferon gamma; IgA, immunoglobulin A; TMC, trimethylchitosan; DC, dendritic cells; PLGA, poly(lactic-co-glycolic acid); MDP,
muramyl dipeptide; LPS, lipopolysaccharide; HA, hyaluronic acid; MCC, mono-N-carboxymethyl chitosan; CTL, cytotoxic T lymphocyte; IL-4, interleukin 4; SARS-CoV, severe acute respi-
ratory syndrome coronavirus; JE, Japanese encephalitis; TLR, Toll-like receptor; IgE, immunoglobulin E.
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in a single nanostructure, and open room for thepotential ofmodulating
immunity towards the cellular pathway using a needle-free vaccination
approach.
A chitosan derivative with higher water solubility and pH-
independent cationic nature, N-trimethyl chitosan (TMC), has also
been evaluated for the preparation of nanovaccines. The intraduodenal
immunization of OVA-loaded TMC nanoparticles to mice, provided a
similar immune response than conventional chitosan nanoparticles, in
terms of IgG levels, and showed an improved ability to induce DC
maturation (Slütter et al., 2009). The behaviour of OVA-loaded TMCnanoparticles was also compared with that of OVA-loaded PLGA and
OVA-loaded TMC-coated PLGA nanoparticles, upon intranasal or intra-
muscular administration to healthy mice. While all formulations could
enhance the immune response following intramuscular administration,
only TMC nanoparticles were able to elicit an immune response after in-
tranasal administration, a fact that was attributed to their increased in-
teraction with the nasal mucosa (Slütter et al., 2010a). The efficacy of
these nanoparticles was also compared with that of TMC–OVA conju-
gates, previously developed for intramuscular administration, which
had shown adjuvant activity similar to that of TMC nanoparticles
(Slütter et al., 2010c). Upon intranasal administration of both TMC–
Fig. 2. Images of the lower body of rabbits injectedwith 111In-radiolabelled chitosan nanocapsules (upper row) or with a control solution of 111InCl3 (lower row), acquired 4, 24, and 48 h
post injection. A depot formation in the injection site, as well as a slow drainage and further accumulation in the popliteal lymph node, can be observed in the case of the nanocapsules.
Yellow arrow: injection site (rear foot); green arrow: popliteal lymph node; blue arrow: iliac lymph nodes; orange arrows: kidneys; circle: external standard.
Adapted with permission from Vicente et al. (2014).
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results have shown the conjugates' superiority in terms of the IgG and
IgA levels elicited, a fact attributed to the higher uptake of these struc-
tures by the nasal epithelium (Slütter et al., 2010b).
In another study, TT-loaded TMC nanoparticles were compared
to TT-loaded chitosan nanoparticles, upon either intranasal or subcuta-
neous administration tomice, with the corresponding polymer solution
as a control. The results evidenced the similar behaviour of both types of
nanoparticles in terms of IgG response (Sayın et al., 2008). Finally, TMC
has also been used in combinationwith hyaluronan (HA) (Verheul et al.,
2011). Despite the observation of an immune response upon intranasalFig. 3. Serum IgG levels achieved after intranasal immunization (two doses at 0 and
4 weeks, indicated by the arrows) of healthy mice with rHBsAg-imiquimod-loaded chito-
san nanocapsules, rHBsAg-loaded chitosan nanocapsules (without imiquimod) and
rHBsAg-loaded nanoemulsion (control group without chitosan). *p b 0.05 between
rHBsAg-loaded chitosan nanocapsules (with and without imiquimod) and the rHBsAg-
loaded nanoemulsion; **p b 0.05 between rHBsAg-imiquimod-loaded chitosan nano-
capsules and the other two formulations.
Reproduced with permission from Vicente et al. (2013b).administration tomice, the benefits of incorporating HA to the formula-
tion remain unclear, since comparative studieswith plain TMCnanopar-
ticles were not included in this work.
The last example corresponds to OVA-loaded TMC nanoparticles
that co-encapsulate additional immunostimulant molecules, namely
lipopolysaccharide (LPS, TLR-4 agonist), CpG (TLR-9 agonist), Pam3CSK4
(TLR-2 agonist), muramyl dipeptide (MDP, NOD-like receptor 2 ligand)
and cholera toxin B subunit (CTB, GM1 ganglioside receptor ligand) (Bal
et al., 2012). Upon intranasal administration to healthy mice, a Th2-
biased response was reported in most cases (except for CpG), being
the highest response achieved with nanoparticles co-associating MDP.
3.1.2. Nucleic acid-based nanovaccines
3.1.2.1. Parenteral vaccination with chitosan/nucleic acid-based
nanovaccines. Chitosan nanoparticles have also been developed for
the delivery of plasmid DNA for immunization purposes (Gomes et al.,
2014). In a couple of examples, chitosan nanoparticles have been loaded
with plasmid DNA encoding for the recombinant major outer mem-
brane protein of Chlamydia trachomatis (Cambridge et al., 2013) or for
three T-cell epitopes of Esat-6, a Mycobacterium tuberculosis antigen
critical for virulence (Feng et al., 2013). In the first case, results showed
high expression levels of the C. trachomatis protein after intramuscular
administration tomice, both at the site of injection and also systemically
(i.e. spleen) (Cambridge et al., 2013). In the second example, the results
obtained after intramuscular administration tomice indicated a protec-
tion against aM. tuberculosis challenge associated to strong Th1 and cy-
totoxic T lymphocyte (CTL) responses (Feng et al., 2013).
3.1.2.2. Mucosal vaccination with chitosan/nucleic acid-based
nanovaccines. Chitosan nanoparticles have been tested for intranasal
immunization against several pathogens. One example refers to chito-
san nanoparticles that associate a plasmid encoding a multi-epitope
protein againstM. tuberculosis (pHSP65pep). This formulation provided
the administered mice with an adequate protection against bacterial
challenge, protection that was associated to significant T-cell responses
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chitosan nanoparticles were loaded with a plasmid encoding for
antigen 85B together with a second plasmid encoding an autophagy-
inducing factor (myc-mTOR) (Meerak et al., 2013). After immuniza-
tion of mice with a subcutaneous prime and two intranasal boosts
(2-week intervals), results proved a synergistic effect, due to the co-
administration of both plasmids, in terms of immune response. Chito-
san nanoparticles have also been evaluated against hepatitis B, upon as-
sociation of a plasmid encoding the hepatitis B surface antigen (pRc/
CMV-HBs) (Khatri et al., 2008b). Results showed a Th1-biased response
after intranasal administration to mice, which was accompanied of in-
creased IgA levels in nasal, salivary and vaginal secretions.
In an attempt to further improve their efficacy as DNA carriers for
intranasal immunization, chitosan nanoparticles loaded with a plasmid
encoding the nucleocapsid protein of severe acute respiratory syn-
drome coronavirus (pVAXN) were decorated with a bifunctional fusion
protein (bfFP) targeted at the DC surface receptor DEC-205, and also
with an antibody binding the DC receptor CD40, to stimulate these
cells. Mice were immunized either intranasally or intramuscularly
with (i) naked pVAXN, (ii) pVAXN-loaded nanoparticles, (iii) bfFP
decorated pVAXN-loaded nanoparticles, and (iv) bfFP and aCD40 deco-
rated pVAXN-loaded nanoparticles. The results indicated that the nano-
particles decorated with both molecules (bfFP/aCD40 approach), were
more efficient in terms of IgG and IgA responses irrespective of the
administration route (Raghuwanshi et al., 2012). The incorporation of
immunostimulatory molecules in chitosan-based nanocarriers was
also evaluated. In detail, Heuking et al. (Heuking and Borchard, 2012;
Heuking et al., 2009) grafted TLR agonists to TMC and prepared nano-
particles with the model plasmid pGFP. In vitro results showed
that the incorporation of Pam3Cys (TLR-2 agonist) and 9-benzyl-8-
hydroxyadenine (TLR-7 agonist) enhanced IL-8 release, a cytokine re-
sponsible for the attraction of leukocytes to the local of infection.
Chitosan nanovaccines have also been tested for oral immunization
(Li et al., 2009;Oliveira et al., 2012). An interestingwork refers to the as-
sociation of plasmid DNA encoding Der p2, an allergen from house dust
mites, to chitosan nanoparticles, which were orally administered to
healthy mice. The results evidenced high IgG2 and low IgE levels, to-
gether with high IFN-γ and low IL-4 secretion, in accordance with a re-
duction of the allergic response (Li et al., 2009). In another work, a
chitosan derivative containing imidazole moieties (CSimi) was used in
the preparation of nanoparticles for the delivery of a plasmid encoding
a Schistosoma mansoni antigenic protein (Rho1-GTPase) (Oliveira
et al., 2012). After oral administration of three doses of pDNA-loaded
CSimi nanoparticles to healthy mice (weeks 1, 3 and 5), the animals
were challenged with the pathogen and results evidenced a reduction
of the main pathogenic effect, liver granulomatosis, in comparison
with the control animals that received PBS. Interestingly, one of the con-
trol groups that received blank chitosan nanoparticles (without anti-
gen) also promoted a strong worm burden reduction in comparison
with the control group, a fact thatwas attributed to an immune reaction
against chitosan, since other similar carbohydrates are present in the
parasite structure.
Chitosan-coated liposomes have also been described for mucosal
immunization (Chen et al., 2013; Khatri et al., 2008a). In detail, glycol
chitosan-coated liposomes, which associated a plasmid encoding the
surface hepatitis B antigen (pRc/CMV-HBs), were administered intrana-
sally tomice (Khatri et al., 2008a). The results, in terms of IgG responses,
were similar to those observed in the control mice receiving the con-
ventional alum-adsorbed encoded antigen (HBsAg) intramuscularly.
However, the coated liposomes promoted a superior cell response as
evidenced by the IL-2 and IFN-γ levels. Moreover, IgA levels in nasal,
vaginal, and salivary secretions were only detected in the animals im-
munized with the chitosan-coated liposomes. In another example,
chitosan-coated liposomes were loaded with a plasmid encoding a sur-
face antigen of Streptoccocus mutans, for dental caries prevention, and
their efficacy was compared to that of plasmid-loaded chitosannanoparticles and plasmid in solution (Chen et al., 2013). After intrana-
sal administration to healthy mice, chitosan-coated liposomes elicited
an improved immune response, whichwas related to the controlled an-
tigen released and to the improved interaction of the plasmid-loaded
nanoparticles with the nasal mucosa.
Globally, these results evidence the increasing interest in chitosan-
based nanovaccines particularly for either parenteral ormucosal immu-
nization strategies using both protein antigens and nucleic acid-based
antigens. This potential is associated to the ability of chitosan-based
nanosystems to interactwithmucosal tissues and to their specific distri-
bution into the lymphatic system. This accumulated information is firm-
ly consolidating the potential of this polysaccharide as a biomaterial for
the engineering of new vaccines.
3.2. Dextran as a biomaterial for nanoengineering antigens
Dextran is one of the most studied α-glucans in drug and antigen
delivery. This polymer of α-(1,6)-glucan with α-(1,3) branches is ob-
tained from bacteria, particularly from Lactobacillus, Leuconostoc and
Streptococcus species (Raemdonck et al., 2013). Native bacterial dextran
has high molecular weight and is water soluble, which is a useful char-
acteristic for pharmaceutical formulation purposes. Also, its structure,
particularly its hydroxyl groups, allow for easy functionalization and
chemical modifications (Baldwin and Kiick, 2010). Finally, the bio-
compatibility and biodegradability of this biomaterial, together with
its high availability and reduced cost of production, make it very attrac-
tive for the nanoengineering of antigens (Baldwin and Kiick, 2010;
Raemdonck et al., 2013).
It is important to mention that dextran has GRAS status given by the
FDAand has been used in humans for a very long time,mainly as plasma
volume expander and anti-thrombotic agent (de Belder, 1996). Its
sulfated derivative, dextran sulfate (DS), has also been approved by
the FDA as a component of apheresis columns, used to remove low
density lipoprotein (LDL) from the blood (www.fda.gov). Since the
70s, the immunomodulating properties of dextran sulfate and its poten-
tial use as adjuvant have also been studied. Overall the results reported
so far have shown its ability to increase the antibody- and cell-mediated
immune responses in animal models (Kerlin and Watson, 1987;
McCarthy et al., 1977). This derivative, when administered “ad libitum”
with drinkingwater at a 3% (w/v) concentration, has also been associat-
edwith strong pro-inflammatory effects, being used as an inducer of in-
flammatory diseases such as colitis in mice for the development of
animal models of this disease (Laroui et al., 2012). Diethylaminoethyl
(DEAE)-dextran is another derivative with adjuvant properties, studied
mostly for veterinary vaccines (Finnerty et al., 1994). Nevertheless, the
mechanism of action of this derivative is still not well understood and
requires further research (Cox and Coulter, 1997; Petrovsky and
Cooper, 2011).
3.2.1. Protein nanovaccines
As in the case of chitosan, the polysaccharide dextran has been ex-
plored as a biomaterial for nanoengineeringof protein antigens. Howev-
er, in this case, and despite its reported immunostimulant properties,
the activity has been limited to a few studies, as described below.
3.2.1.1. Parenteral vaccination with dextran-based nanovaccines. Dextran
nanoparticles containing OVA in combination with LPS were developed
and administered intravenously to mice (Shen et al., 2013). The results
showed that these carriers were efficiently internalized by DCs, and in-
ducedOVA-specific T-cell proliferation (CD4+ and CD8+ T cells), aswell
as a stronger Th2-biased immune response, in comparisonwith the con-
trols (empty dextran nanoparticles, LPS-loaded nanoparticles and OVA-
loaded nanoparticles). Dextran nanoparticles have also been evaluated
for the encapsulation of immunostimulant molecules such as CpG or
poly(I:C) (Peine et al., 2013). In vitro studies show as, upon incubation
with macrophages, these nanosystems elicited higher production of
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provement in the adjuvant potential of poly(I:C) and CpG.
The incorporation of dextran into chitosan-based nanosystems has
recently been reported for the delivery of the capsid protein of HIV-1
(p24) and pertussis toxoid (PTX) (Drogoz et al., 2008; Sharma et al.,
2012). Anionic and cationic chitosan/dextran nanoparticles were pre-
pared bymodulation of themass ratio of both polysaccharides, and sub-
sequently loaded with p24. After subcutaneous administration to
healthy mice, both cationic and anionic nanoparticles rendered IgG ti-
tres that were comparable to those elicited by the Complete Freund's
Adjuvant (CFA) (Drogoz et al., 2008). In the case of chitosan/dextran
nanoparticles loaded with PTX (Sharma et al., 2012), the IgG response
observed after subcutaneous administration to mice was significantly
higher than the one elicited by the alum-adsorbed antigen.
Dextran nanoparticles were also prepared in combination with
polyvinylalcohol (PVA), for the encapsulation of a recombinant Bacillus
anthracis antigen (rPA), or resiquimod, a TLR 7/8 agonist (Schully et al.,
2013). These nanoparticles were subcutaneously administered to mice,
either separately or in combination with the alum-adsorbed antigen.
The first observation was a balanced Th1/Th2 immune response in
animals receiving resiquimod. Indeed, the highest levels of IgG and cy-
tokine production were observed with the co-administration of
resiquimod-loaded nanoparticles in combination with rPA-loaded
nanoparticles, or alum-adsorbed rPA; both combinations were respon-
sible for 100% animal survival upon three challengeswith the pathogen.
3.2.1.2. Mucosal vaccination with dextran-based nanovaccines. Dextran-
based nanoparticles have been barely explored for intranasal vaccina-
tion. In a study (Sharma et al., 2013), IgA was associated to dextran
nanoparticles as a possible targetingmoiety towards theM cells present
in the nasal mucosa. After a single intranasal administration of
fluorescent-labelled nanoparticles to healthy mice, the fluorescence
levels for IgA-decorated dextrannanoparticles, analysed by confocalmi-
croscopy,were particularly high in the nasal-associated lymphoid tissue
(NALT) cells in comparison with other nasal tissue areas. Therefore,
these preliminary data suggest the potential of these nanoparticles for
intranasal immunization.
3.2.2. Nucleic acid-based nanovaccines
Despite the number of studies reported on the use of chitosan nano-
particles for DNA vaccines, no studies have been identified incorporat-
ing dextran into the nanostructures or any other application of
dextran-based nanocarriers in the development of genetic vaccines.
Overall, regardless of the limited number of studies reported so far,
the results achieved with dextran-based systems open room for a
deeper research in this field, particularly in terms of the combination
of this polymer with other immunomodulatory molecules.
3.3. Mannans as biomaterials for nanoengineering antigens
The term “mannan” refers to storage polysaccharides very abundant
in nature, consisting in D-mannose monomers connected by β-(1,4)
bonds. The interest of these polysaccharides relies on their ability to in-
teract with C-type lectins, a group of receptors expressed in APCs (DCs
and macrophages). These receptors are responsible for the recognition
of different carbohydrates present in the cell wall of certain pathogens
and include the mannose receptor (MR), the mannose-binding lectin
(MBL), and others more specific to DCs such as DC-SIGN or DEC-205
(Apostolopoulos et al., 2013).
The recognition process described above leads to the endocytosis or
phagocytosis of pathogens, withmajor importance in the innate immu-
nity process, eliciting complement activation and triggering inflamma-
tion (Petersen et al., 2001; Petrovsky and Cooper, 2011). Moreover,
interactions with specific DC C-type lectins have been correlated with
DC trafficking and induction of both humoral and cellular responses
(Apostolopoulos et al., 2013).The targeting of nanovaccines to APCs using this approach has been
applied to different antigens, as discussed below. Nevertheless, it is
important to be aware of a limitation of this strategy, the ubiquitous
presence of mannan receptors in a variety of cells, including immune
cells, epithelial cells (in the retina),mesangial cells (in kidney) andmus-
cular (in trachea) cells (Joshi et al., 2012).
3.3.1. Protein nanovaccines
The functionalization of nanovaccines with mannose residues for
specific targeting of protein and peptide antigens to DCs, macrophages
and B cells, has been evaluated in murine and human in vitro models
(Al-Barwani et al., 2014; Ghotbi et al., 2011; Thomann-Harwood et al.,
2013).
Polymeric nanoparticles based on a copolymer of poly-ε-
caprolactone (PCL) and polyethyleneglycol (PEG), functionalized with
mannan, were optimised for the encapsulation of the human basic
fibroblast growth factor (bFGF), for cancer immunotherapy, and admin-
istered to healthy mice (Gou et al., 2008). The fundamental role of
mannan was evidenced in view of the significantly higher IgG levels
achieved, in comparison with the control formulations, i.e. non-
targeted nanoparticles and the alum-adsorbed antigen. Moreover, the
immune response was biased towards the Th1 pathway, as shown by
an increased level of IgG2a, which is particularly important to confront
tumour cells. In another study, OVA-loaded mannan-decorated PLGA
nanoparticles were also found to elicit higher T-cell responses when
comparedwithOVA-loadednon-decorated PLGAnanoparticles (Hamdy
et al., 2011), after subcutaneous administration to mice. Finally, in vitro
macrophage uptake studies performed using poly(2-hydroxiethyl
methacrylate-co-methacrylic acid) (P(HEMA-co-MAA)) nanogels, load-
ed with OVA, revealed a high internalization that was accompanied of a
high production of co-stimulatory molecules, such as CD86, CD40 and
CD80 (Durán-Lobato et al., 2014).
Glucomannan, a polymer of β-1,4 linked D-mannose and D-glucose,
has also been studied for the preparation of nanoparticles (Alonso-
Sande et al., 2006, 2009; Harde et al., 2014; Jain et al., 2014a,b). Bovine
serum albumin (BSA)-loaded chitosan nanoparticles were functional-
ized with glucomannan with the aim of achieving an improved interac-
tionwithmacrophages (Harde et al., 2014). Upon oral administration of
these decorated nanoparticles to mice, the immune response, in terms
of IgG and IgA titres and cytokine production, was significantly higher
with respect to non-functionalized nanoparticles. A novel approach re-
cently explored comprises the modification of bilosomes (non-ionic
surfactant-based nanovesicles containing bile salts) with glucomannan
for oral antigen delivery (Jain et al., 2014a,b). BSA and TT were used
as model antigens and in vitro studies showed that glucomannan-
modified bilosomes had an increased uptake by macrophages in com-
parisonwith the unmodified ones. This translated into stronger system-
ic and mucosal immune responses following oral administration to
mice.
3.3.2. Nucleic acid-based nanovaccines
Nanoengineering of nucleic acids with mannan has been mainly
achieved through the synthesis of cationic derivatives of mannan (Lu
et al., 2007; Ruan et al., 2014; Tang et al., 2008, 2009). For example, a
cationic mannan-spermine copolymer was engineered for complexa-
tion of a model pDNA (pGL3), and the transfection efficiency was tested
in a panel of immortalised cell lines, includingmacrophage and dendrit-
ic cells. The results showed high transfection levels in macrophages,
which were associated to the receptor-mediated internalization of the
mannan complexes (Ruan et al., 2014).
Polymer conjugates of mannan (in the oxidized or reduced form)
and poly-L-lysine (PLL) have also been used for the complexation of
pDNA encoding MUC1, a tumour-associated antigen, for anticancer im-
munotherapy. Upon intradermal immunization, these nanovaccines
lead to increased T cell activity and antibody production, which
protected animals against a tumour challenge with MUC-1 expressing
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ability of these nanovaccines to induce DC maturation, through a TLR-2
dependent pathway, and to mediate the cross-presentation of antigens
in vivo (Tang et al., 2009).
Mannan-modified cholesterol has also been synthesized and used
for the preparation of functionalized cationic liposomes that associate
a plasmid encoding a melanoma-associated antigen (pUb-M) (Lu
et al., 2007). Mice were immunized through intraperitoneal route
with this prototype, using liposomes prepared with unmodified choles-
terol and naked plasmid DNA as controls. Results evidenced increased
gene delivery in splenic macrophages and DCs, achieved via mannose
receptor, and a higher specificity of CTL activity with the functionalized
liposomes. More importantly, after challenging the animals through the
injection of tumour cells, the group treated with the mannan-targeted
nanosystems showed rejection of the injected cells, suppression of
their growth and increasing survival.
In general, this work highlights the potential interest of mannan as a
targeting agent that may improve the ability of nanosystems to interact
with the immunocompetent cells. Further studies are necessary in order
to assess the specific benefit of this strategy.
3.4. Beta glucans as biomaterials for nanoengineering antigens
β-Glucans are a group of very different polymers of glucose, varying
in chain length as well as in number and position of branches. These
polysaccharides can be found in the cell walls of many organisms,
from bacteria to yeast and even some species of seaweed (Goodridge
et al., 2009). Some of them, such as β-1,3(D)-glucan (known as baker's
yeast, from S. cerevisae) and β-glucans from Ganoderma lucidum myce-
lium and from Aureobasidium pullulans, have GRAS status given by the
FDA and are used as food ingredients (www.fda.gov). In terms of
immunomodulating properties, most of the research has been done
with non-cellulosic β-(1,3) or β-(1,6)-glucans such as curdlan (from
Alcaligenes faecalis), laminarin (from Laminaria digitata), lentinanFig. 4. Schematic representation of beta glucan recognition by immune cell receptors. The twom
plement receptor 3) andDectin-1. The interaction of beta glucan-containing fungi and bacteria s
the complement activation and particle opsonisation for phagocytosis (CR3 recognition), or, on
enhancement of particle phagocytosis by other pathways (Dectin-1 recognition). Moreover, in
response process may also be a relevant feature of beta glucan-containing structures once reco(from Lentinus edodes), pleuran (from Pleurotus ostreatus) and zymosan
(from Saccharomyces spp.) (Goodridge et al., 2009; Petrovsky and
Cooper, 2011).
The role of beta glucans in the immune response has already been
explored for several decades. Their presence in the structure of different
bacteria and fungi makes them easily recognizable by the PRRs, acting
as natural PAMPs (Soltanian et al., 2009). However, the adjuvant prop-
erties of one specific beta glucan cannot be generalized to others, due to
differences in parameters such as size, branching and molecular struc-
ture (Adams et al., 2008; Barsanti et al., 2011; Sletmoen and Stokke,
2008; Soltanian et al., 2009).
The intervention of beta glucans in immunity is mainly due to their
interaction with specific cell receptors, as pictured in Fig. 4. Though
both types of recognition lead to similar biological effects, it is worth de-
scribing in further detail each one of them. On one hand, CR3 (comple-
ment receptor 3), widely present in myeloid cells such asmacrophages,
DCs and natural killer (NK) cells, was the first receptor described for the
recognition of beta glucans. Though the biological effects of this specific
interaction are not yet fully understood, it has already been shown that
it leads to complement activation and subsequent opsonisation, follow-
ed by internalization of the structures (Bose et al., 2013; Goodridge
et al., 2009; Soltanian et al., 2009). On the other hand, Dectin-1, a type
II transmembrane protein present in myeloid cells, is the most studied
β-glucan receptor. The interaction of beta glucan-containing microor-
ganisms or synthetic particles with this receptor mediates several pro-
cesses such as reactive oxygen species (ROS) and cytokine production,
being also a trigger for the internalization of pathogens via phagocytosis
(Goodridge et al., 2009; Lipinski et al., 2013; Mochizuki and Sakurai,
2011).
This interaction has led to the use of beta glucans also as targeting
moieties for the enhancement of specific immune responses. For exam-
ple, in the work of Dube et al. (2014), chitosan-coated PLGA nanoparti-
cles were functionalized with 1,3-β-glucan from Euglena gracilis for
Dectin-1 targeting. As a result, an increased intracellular delivery ofain beta glucan receptors in APCs such asmacrophages and dendritic cells are CR3 (com-
pecies, aswell as synthetic glucan nanoparticles, with these cellsmay lead, on one hand, to
the other hand, to the secretion of proinflammatory cytokines and ROS, together with the
this last case, the ability to trigger the action T helper (Th17) cells in the adaptive immune
gnized by Dectin-1.
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inflammatory reaction with relevant production of reactive oxygen
and nitrogen species was reported.
3.4.1. Protein nanovaccines
The above indicatedproperties of the beta glucans have attracted the
attention of a few researchers who have explored their use as antigen
carriers. A conjugate of β-mannan, tetanus toxoid and laminarin (from
Laminaria digitata) was evaluated for the development of a vaccine
against Candida albicans (Lipinski et al., 2013). This new conjugated an-
tigen was able to promote receptor-based DC uptake mediated by the
interaction of laminarin with Dectin-1, altogether resulting in an en-
hanced cytokine production (IL-4, IL-6 and TGF-β) and strong IgG anti-
body responses after intraperitoneal or subcutaneous administration to
mice, with IFA as adjuvant (Lipinski et al., 2013).
Given the potential exhibited by beta glucans for immunomodu-
lation, it is expected an increasing interest in their use for the develop-
ment of nanovaccines. However, to the best of our knowledge, only one
example relates to the use of the polysaccharide PS4 (isolated from
G. lucidum mushrooms), with strong immunomodulating properties,
based on the regulation of TNF-α, nitric oxide (NO) and cytokine pro-
duction through interactionwith TLR2, for the preparation of nanosized
complexes with poly(I:C) (Tincer et al., 2011). IgG responses observed
after intraperitoneal administration of OVA-loaded PS4 nanoparticles
to mice were higher than those elicited by the controls (i.e. physical
mixtures of PS4 and OVA, or poly(I:C) andOVA). This positive in vivo re-
sponsewas correlated to an increased cytokine production after incuba-
tion of these nanoparticles with macrophages.
3.4.2. Nucleic acid-based nanovaccines
Some studies have also highlighted the potential of beta glucans
for the delivery of nucleic acid antigens. Synthetic cationic glucans ob-
tained from G. lucidum have been reported to efficiently associate a
model pDNA (pGL-3 encoding luciferase), and to achieve an adequate
transfection in human embryonic kidney transformed cells (HEK293T)
(Wang et al., 2012). Another example is the one making use of
schizophyllan (SPG) complexed with TNF-α oligonucleotides (ODN)
for delivery to macrophages, which are their therapeutic target in in-
duced hepatic damage. Upon intraperitoneal administration of either
the SPG-ODN complex or both components individually tomice bearing
LPS-induced hepatic damage, the ODN were efficiently delivered to
APCs through Dectin-1 targeting and exhibited an encouraging thera-
peutic effect (Mochizuki and Sakurai, 2011).
Overall, beta glucans present intrinsic properties that increase the
interest in their use for vaccine development, as demonstrated in this
review. Nevertheless, the results achieved with these polymers are
still preliminary, particularly in the case of the development of antigen
nanocarriers, and the real potential of beta glucans in this field is yet
to be demonstrated.
4. Concluding remarks
Throughout the past decades, several innovative biological tech-
niques have been applied to the design and development of safer and
more effective vaccines. However, the need for potent adjuvants that
can enhance the immune response elicited by modern antigens has
also grown and is nowadays an important research field. Within this
frame, nanotechnology has been playing an increasingly important
role, given the appropriate features offered by nanocarriers to the ad-
ministration of antigens. These include their particulate nature, control-
lable particle size, ability to protect antigens from degradation and to
deliver them in a controlled manner, possibility to overcome mucosal
routes, and ability to include co-stimulatory molecules that may en-
hance the global adjuvant effect of the nanocarrier.
In this context, the use of polysaccharides in the development
of novel nanovaccines has represented a crucial step. Due to theinteresting intrinsic properties of chitosan, such as its mucoadhe-
siveness and effect in the activation of macrophages, both particularly
relevant for vaccine delivery, this polysaccharide has been the most
studied one in the development of nanovaccines. Nevertheless, the
use of other polysaccharides in this field is slowly growing and even
though many of them are barely known as nanovaccine components,
their recognized immunomodulating properties open room for further
research and progress in this particular area.
Globally, recent work in nanovaccine development has demonstrat-
ed the potential of this strategy to confront current barriers in vaccina-
tion. Nevertheless, it is important to take into consideration that the
combination of the biomaterials used in a specific formulation, the cho-
sen antigen and the route of administration of the nanovaccines will be
critical factors influencing the final outcome of the vaccination strategy.
5. Future perspectives
The use of biomaterials, especially natural polymers, for the prepara-
tion of antigen delivery systems, is one of the main tendencies on the
field of vaccination. However, the natural origin of these materials is
often responsible for high variability in the characteristics of each spe-
cific polymer and, therefore,may lead to variable and even controversial
results in terms of their adjuvant activity. This is also a challenge in
terms of the progress of these innovative vaccine formulations towards
clinical development and commercialization. Therefore, it is expected
that the next few years bring deeper knowledge in terms of themecha-
nism of action of these polymers, whichmight drive the path for amore
rational design of polysaccharide-based nanoparticle adjuvants.
Other particular issues, such as the achievement of thermally stable
formulations that can avoid the cold chain of vaccine storage, might be
one of the challenges nanovaccines are likely to face in the next steps of
the way. Finally, the optimization of the preparation methods used in
nanovaccine development in order to adequately manufacture them
at the industrial level is a major topic that should be addressed in the
near future of this field. The combination of this accumulated knowl-
edge could be the necessary driving force to take polysaccharide-
based and other nanovaccines towards the next level and ultimately
to achieve clinical use.
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